Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

MK-677 vs HGH: Secretagogue vs Growth Hormone

MK-677 vs HGH: Secretagogue vs Growth Hormone MK-677 vs HGH compared: oral secretagogue vs injectable growth hormone, mechanisms, IGF-1 elevation, cost, side effects, evidence grades, and research applications. MK-677 (ibutamoren) is an oral ghrelin receptor a

This comparison does not assign a generated winner or score.

MK-677 vs HGH: Secretagogue vs Growth Hormone MK-677 vs HGH compared: oral secretagogue vs injectable growth hormone, mechanisms, IGF-1 elevation, cost, side effects, evidence grades, and research applications. MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates endogenous growth hormone release, increasing IGF-1 levels by 40-90% with a convenient once-daily oral dose. HGH (somatropin) is recombinant human growth hormone administered via subcutaneous injection, providing direct supraphysiological GH elevation. This comparison examines the fundamental trade-off between oral convenience and lower cost (MK-677) versus precise dosing and maximal GH elevation (HGH). Mechanism Ghrelin receptor (GHSR) agonist; stimulates endogenous GH Exogenous recombinant human growth hormone Evidence Grade B+ A+ Route Oral (capsule or liquid) Subcutaneous injection Typical Dose 10 - 25 mg/day oral 1 - 4 IU/day SC injection Half-Life ~24 hours ~3-4 hours (GH clearance) IGF-1 Increase 40 - 90% above baseline 100 - 300%+ (dose-dependent) GH Release Pattern Amplified pulsatile (endogenous) Direct exogenous bolus Best For Budget GH optimization, sleep, appetite Maximum GH elevation, precise dosing, anti-aging FDA Status Not FDA-approved; investigational FDA-approved (GH deficiency) Cost (monthly) $30 - $60 $300 - $1,000+ Oral administration (no injections) Dramatically lower cost (10-20x cheaper) 24-hour half-life allows once-daily dosing Preserves natural pulsatile GH secretion Improves sleep quality (deep sleep enhancement) Significant IGF-1 elevation (40-90%) Significant appetite increase (ghrelin pathway) May increase cortisol and prolactin Water retention and bloating common Cannot achieve supraphysiological GH levels May worsen insulin sensitivity with long-term use Not FDA-approved FDA-approved with extensive safety data Precise, dose-dependent GH elevation Strongest evidence for body composition changes No appetite stimulation via ghrelin No cortisol or prolactin elevation Can achieve supraphysiological levels when desired Requires daily subcutaneous injection Significantly higher cost ($300-1,000+/month) Suppresses natural GH production during use Potential for joint pain, carpal tunnel at high doses Risk of counterfeit products in research market Short half-life requires consistent timing Choose MK-677 if: Your research goals include moderate GH/IGF-1 optimization within physiological ranges, improved sleep quality, or long-term GH support at an accessible cost. MK-677 is ideal for protocols where injectable administration is impractical and budget is a primary constraint. Its oral convenience and 24-hour half-life make it the simplest GH-enhancing compound available. Choose HGH if: Your research requires precise GH dosing, supraphysiological GH levels, the strongest evidence base, or FDA-approved status. HGH is the gold standard for growth hormone research with decades of clinical data. It is essential for protocols studying body composition, anti-aging, or GH deficiency where maximum and controllable GH elevation is needed. Note: MK-677 is not a replacement for HGH in clinical GH deficiency. Its appetite-stimulating effects and insulin sensitivity concerns should be weighed against its cost and convenience advantages. MK-677 increases IGF-1 by 40-90% but cannot match HGH's supraphysiological peaks. For moderate GH optimization within upper-normal ranges, MK-677 may suffice. For maximum GH elevation and precise dosing, HGH is required. They operate through fundamentally different mechanisms. Yes, MK-677 costs approximately $30-60/month vs $300-1,000+ for pharmaceutical HGH. This 10-20x cost difference is one of MK-677's primary advantages, making GH optimization accessible for extended research protocols. Yes, MK-677 significantly increases appetite through ghrelin receptor activation. HGH does not stimulate appetite through the ghrelin pathway. MK-677's hunger effect typically diminishes after 2-4 weeks but can be counterproductive for fat loss protocols. Verified Research Suppliers ★ LiveWell Peptides — Preferred Vendor • cGMP Certified Preferred vendor Core Peptides — Third-party tested — Broad catalog Biotech Peptides — USA-based Related Resources

More references

Related material

Comparison

Side-by-Side Comparison

Mechanism Ghrelin receptor (GHSR) agonist; stimulates endogenous GH Exogenous recombinant human growth hormone Evidence Grade B+ A+ Route Oral (capsule or liquid) Subcutaneous inj…

View details →